Vaxcyte, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Vaxcyte, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($212.83M) | Nov 4, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($166.57M) | Aug 6, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($166.57M) | Nov 4, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($140.72M) | May 7, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($140.72M) | Nov 4, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($140.72M) | Aug 6, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($103.12M) | Nov 4, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($128.70M) | Nov 4, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($128.70M) | Aug 6, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($95.02M) | May 7, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($95.02M) | Nov 4, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($95.02M) | Aug 6, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($92.66M) | Nov 5, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($68.34M) | Aug 6, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($68.34M) | Nov 5, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($60.46M) | May 8, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($60.46M) | Aug 6, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($60.46M) | Nov 5, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($57.92M) | Nov 6, 2023 |
| Q3 | 2023 | Jun 30, 2022 | ($48.53M) | Nov 6, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($242.38M) | Nov 4, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($226.22M) | Aug 6, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($180.79M) | May 7, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($139.92M) | Nov 4, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($152.98M) | Aug 6, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($114.47M) | May 7, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($113.03M) | Nov 5, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($87.15M) | Aug 6, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($71.19M) | May 8, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($58.58M) | Nov 6, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($47.89M) | Aug 8, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($39.22M) | May 8, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($26.95M) | Nov 7, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($23.73M) | Aug 8, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($23.14M) | May 9, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($21.31M) | Nov 10, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($21.22M) | Aug 11, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($27.60M) | May 11, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($12.14M) | Nov 12, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($12.23M) | Aug 12, 2020 |